Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company

MT Newswires Live

Mar 04

Rhythm Biosciences (ASX:RHY) secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.

The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.

Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616306119"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616306119\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616306119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616306119","market":"sg","top_or_hot":-1,"title":"Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.</p><p>The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.</p><p>Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Biosciences Secures Supply Deal With UK Cancer Diagnostics Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-04 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.</p><p>The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.</p><p>Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616306119","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616306119","pubTimestamp":1772586033,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rhythm Biosciences  secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","RHY.AU":"RHYTHM BIOSCIENCES LTD"},"translate_title":"Rhythm Biosciences与英国癌症诊断公司达成供应协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHY.AU":1},"content_text":"Rhythm Biosciences (ASX:RHY) secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}